Keysight Technologies enters the post-earnings week as one of the Street's most unanimously upgraded names, with analysts racing to lift targets after Tuesday's results triggered a wave of positive revisions — even as the stock pulled back roughly 5% on the week.
The clearest signal this week is the sheer breadth of upward analyst revisions. Every firm that updated its model raised its price target, and the moves were not incremental. UBS lifted its buy-rated target from $340 to $420 on Wednesday. Wells Fargo pushed its overweight target from $300 to $390. Barclays moved from $320 to $387. Susquehanna and Baird both raised as well. Morgan Stanley, the lone equal-weight holdout in the group, bumped from $305 to $350 — still well below the pack. The consensus now sits at a mean target of $371, implying roughly 8% upside to the current $344 close. Eight of nine covering analysts are at a buy-equivalent rating, with only that one sell on the board.
Options positioning tells a sharply different story from the cautious bears. The put/call ratio collapsed to 0.61 on Tuesday — the lowest of the past 52 weeks and more than four standard deviations below its 20-day average of 1.10. That is an unusually aggressive swing toward call demand in a single session, suggesting options traders rushed to position for upside following the earnings release. The contrast with the prior month is stark: the PCR had been running above 1.10 for most of April, reflecting elevated hedging ahead of the print.
Short interest is simply not a factor here. Bearish positioning is minimal at 1.3% of the free float, and availability is essentially unlimited — the lending pool holds far more shares than anyone is trying to borrow. Cost to borrow has eased back to 0.44% after briefly spiking to 0.79% mid-month, which itself was a non-event at these levels. The ORTEX short score of 28 confirms there is no meaningful short-side pressure on the stock.
Valuation tells a more measured tale. At roughly 36x trailing earnings and 29x EV/EBITDA on the snapshot data, Keysight is not cheap, and the EPS-forward momentum score of 28 out of 100 is below the median — meaning forward earnings expectations have not yet moved as decisively as the targets would imply. The earnings yield at 2.8% leaves limited margin for macro disappointment. On the institutional side, Columbia Management added nearly 792,000 shares as recently as April 30, making it one of the more active additions in the ownership register. FMR added 611,000 over the same period. These are meaningful position builds, though they predate this week's post-earnings repricing. On the insider front, CEO Satish Dhanasekaran sold 500 shares on May 18 at $340 — a modest, low-significance transaction in the context of a stock that has roughly doubled from its January lows.
The week's tension is straightforward: the Street is nearly unanimous on direction but the stock is trailing its upgraded targets after the print, with peers like GLW and AEIS both down sharply — 11% and 11% respectively on the week — suggesting the broader electronic equipment group is under pressure even as Keysight catches a specific post-earnings bid. What to watch next is whether the EPS estimate revisions that typically follow a target-price sweep begin to show up in the forward consensus, and whether the current-period order book commentary sustains the bull case for a cyclical recovery in test and measurement demand.
See the live data behind this article on ORTEX.
Open KEYS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
